EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adjuvant-driven antibody response to use cows as biofactories of anti-SARS-CoV-2 neutralizing antibodies in colostrum

E B Gaspar, D J B Orts, H H M Costa, P E A Souza, N T B S Honório, C R Prudêncio, L P Silva, C C Bonatto, A P A Bastos, P P Adriani, G S de Oliveira, R Domingues und 8 weitere

Journal of Dairy Science · 2025

DOI: 10.3168/jds.2024-25930 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Dairy Science, 2025. Verfasst von E B Gaspar und 19 weiteren Autor:innen. Beteiligte Einrichtung: Embrapa Dairy Cattle, Brazilian Agricultural Research Corporation, Juiz de Fora, Minas Gerais, Brazil 36038-330. Hauptthemen laut MEDLINE: Colostrum, Antibodies, Neutralizing, Antibodies, Viral, SARS-CoV-2. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Embrapa, National Council for Scientific and Technological Development, Minas Gerais State Foundation of Support to the Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cows produce a substantial amount of immunoglobulin in the colostrum, and nutraceutical products derived from these antibodies are gaining attention for their potential role in human viral disease prevention. The objective of our study was to develop an immunization schedule for pregnant cows to produce hyperimmune colostrum with antibodies presenting high avidity and neutralizing activity against SARS-CoV-2. The recombinant spike receptor-binding domain (RBD) from SARS-CoV-2, expressed using the Expi293F system and purified via Ni-affinity chromatography, was solubilized in (1) saponin (QuilA) or (2) a suspension of potassium and aluminum hydroxide (Alum). Vaccination of pregnant cows and serum sample collection were performed 45, 30, and 15 d before the expected calving date. Serum and colostrum were also collected on the day of parturition. Anti-RBD IgG, IgG1, and IgG2 production, viral neutralization, and antibody avidity were evaluated by ELISA. Cows immunized with recombinant RBD with the QuilA adjuvant produced higher amounts of all antibody subclasses than cows in the Alum group. The viral neutralization index from serum samples was also higher in the QuilA group. Significant differences were not observed in the avidity of antibodies, except for that of IgG2, which was higher in the serum of cows receiving the Alum formulation. As the IgG1 antibody subclass and its avidity are crucial for SARS-CoV-2 neutralization, QuilA might be the optimal adjuvant for producing hyperimmune colostrum in cows. These findings support the use of cows as biofactories of neutralizing antibodies against SARS-CoV-2 or any future emerging and re-emerging viral diseases, with the possibility of simply substituting the subunit antigen in the vaccine formulation. Further tests must be done to evaluate the efficacy of using hyperimmune colostrum as a nutraceutical or purified bovine antibodies as a pharmacological approach for COVID-19 prevention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ColostrumAntibodies, NeutralizingAntibodies, ViralSARS-CoV-2AnimalsCattleFemalePregnancyCOVID-19Immunoglobulin GAdjuvants, ImmunologicSpike Glycoprotein, Coronavirus

Stichwörter der Autor:innen

COVID-19adjuvantbovine colostrumneutralizing antibody

Substanzen

Antibodies, NeutralizingAntibodies, ViralImmunoglobulin GAdjuvants, ImmunologicSpike Glycoprotein, Coronavirus

Autor:innen und Institutionen

  • Embrapa Dairy Cattle, Brazilian Agricultural Research Corporation, Juiz de Fora, Minas Gerais, Brazil 36038-330.
  • Laboratory of CardioBiology, Department of Biophysics, Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil 04023-062; Center of Immunology, Instituto Adolfo Lutz, São Paulo, São Paulo, Brazil…
  • Center of Immunology, Instituto Adolfo Lutz, São Paulo, São Paulo, Brazil 01246-000.
  • Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil 36036-900.
  • Embrapa Genetic Resources and Biotechnology, Brazilian Agricultural Research Corporation, Brasília, Distrito Federal, Brazil 70770-917.
  • Embrapa Swine and Poultry, Brazilian Agricultural Research Corporation, Concórdia, Santa Catarina, Brazil 89715-899.

Förderung

  • Embrapa
  • National Council for Scientific and Technological Development
  • Minas Gerais State Foundation of Support to the Research

Zitieren

APA

Gaspar, E. B., Orts, D. J. B., Costa, H. H. M., Souza, P. E. A., Honório, N. T. B. S., Prudêncio, C. R., Silva, L. P., Bonatto, C. C., Bastos, A. P. A., Adriani, P. P., de Oliveira, G. S., Domingues, R., De Gaspari, E., Portilho, A. I., Martins, M. F., Machado, M. A., Brandão, H. M., Diavão, J., Campos, M. M., & Carvalho, W. A. (2025). Adjuvant-driven antibody response to use cows as biofactories of anti-SARS-CoV-2 neutralizing antibodies in colostrum. Journal of Dairy Science. https://doi.org/10.3168/jds.2024-25930

Vancouver

Gaspar EB, Orts DJB, Costa HHM, Souza PEA, Honório NTBS, Prudêncio CR, et al. Adjuvant-driven antibody response to use cows as biofactories of anti-SARS-CoV-2 neutralizing antibodies in colostrum. Journal of Dairy Science. 2025. doi:10.3168/jds.2024-25930

BibTeX
@article{Gaspar2025,
  author = {Gaspar, E B and Orts, D J B and Costa, H H M and Souza, P E A and Honório, N T B S and Prudêncio, C R and Silva, L P and Bonatto, C C and Bastos, A P A and Adriani, P P and de Oliveira, G S and Domingues, R and De Gaspari, E and Portilho, A I and Martins, M F and Machado, M A and Brandão, H M and Diavão, J and Campos, M M and Carvalho, W A},
  title = {Adjuvant-driven antibody response to use cows as biofactories of anti-SARS-CoV-2 neutralizing antibodies in colostrum},
  journal = {Journal of Dairy Science},
  year = {2025},
  doi = {10.3168/jds.2024-25930}
}
Kostenlos starten →